Therapeutic RNA Delivery for COVID and Other Diseases | Zendy

Dobrowolski Curtis | Zendy; Paunovska Kalina | Zendy; Hatit Marine Z. C. | Zendy; Lokugamage Melissa P. | Zendy; Dahlman James E. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Therapeutic RNA Delivery for COVID and Other Diseases

Author(s) -

Dobrowolski Curtis,

Paunovska Kalina,

Hatit Marine Z. C.,

Lokugamage Melissa P.,

Dahlman James E.

Publication year - 2021

Publication title -

advanced healthcare materials

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.288

H-Index - 90

eISSN - 2192-2659

pISSN - 2192-2640

DOI - 10.1002/adhm.202002022

Subject(s) - rna , in vivo , computational biology , biology , covid-19 , drug delivery , disease , gene , medicine , nanotechnology , infectious disease (medical specialty) , microbiology and biotechnology , genetics , pathology , materials science

RNA can alter the expression of endogenous genes and can be used to express therapeutic proteins. As a result, RNA‐based therapies have recently mitigated disease in patients. Yet most potential RNA therapies cannot currently be developed, in large part because delivering therapeutic quantities of RNA drugs to diseased cells remains difficult. Here, recent studies focused on the biological hurdles that make in vivo drug delivery challenging are described. Then RNA drugs that have overcome these challenges in humans, focusing on siRNA to treat liver disease and mRNA to vaccinate against COVID, are discussed. Finally, research centered on improving drug delivery to new tissues is highlighted, including the development of high‐throughput in vivo nanoparticle DNA barcoding assays capable of testing over 100 distinct nanoparticles in a single animal.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research